Study C of the phase 3 LIBERTY-CUPID trial evaluated dupilumab as add-on therapy to standard of care antihistamines in biologic-naïve patients with CSU who remained symptomatic despite antihistamine ...
LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the Phase 2a Mechanism of Action (MoA) trial, which assessed the mechanistic impact of investigational ...
Results that may be inaccessible to you are currently showing.